Chen Huang
Jiacheng Bi- CAS Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China
Natural killer (NK) cells are cytotoxic innate lymphocytes that play an important role in immune surveillance. The development, maturation and effector functions of NK cells are orchestrated by the T-box transcription factor T-bet, whose expression is induced by cytokines such as IFN-γ, IL-12, IL-15 and IL-21 through the respective cytokine receptors and downstream JAK/STATs or PI3K-AKT-mTORC1 signaling pathways. In this review, we aim to discuss the expression and regulation of T-bet in NK cells, the role of T-bet in mouse NK cell development, maturation, and function, as well as the role of T-bet in acute, chronic infection, inflammation, autoimmune diseases and tumors.
Introduction
The transcription factor T-bet (also known as Tbx21) is an important transcription factor for the immune system, orchestrating multiple types and aspects of immune responses. T-bet belongs to the T-box subfamily, Tbr1, which possesses a 180-200-amino-acid-residue conserved sequence coding for a T box domain for binding of the DNA consensus sequence AATTTCACACCTAGGTGTGAAATT (1). T box domain of T box proteins might bind the target sequence as a dimer, interacting with both the major and the minor grooves of the DNA (2). In addition to the DNA –binding domain (T-box), T box proteins have transcription activation or inhibition domains (3, 4). T-bet is mainly expressed in the lung, thymus, and spleen as determined by Northern blot analysis of multiple organs (5). T-bet is not expressed in resting splenocytes, but is specifically expressed in immune cells such as Th1, NK, B and DC cells after stimulation (5, 6). Tbx21, the gene encoding T-bet, was discovered in an attempt to isolate transcription factors that can direct the tissue-specific expression of Th1 cytokines. The transcription factor was therefore named T-bet, for T box expressed in T cells (5, 7). Later, T-bet expression and function were further revealed in other lymphocyte populations (8).
NK cells are cytotoxic innate lymphocytes, which mainly develop and start the process of maturation from the bone marrow (9), and play an important role in the early defense of intracellular pathogens and immune surveillance of tumors, by rapid production of IFN-γ, as well as other important cytokines and chemokines, and by cytotoxicity against infected or transformed cells (10, 11). Unlike T cells, NK cells do not require priming before displaying cytolytic activity against target cells. Due to the anti-tumor potential of NK cells, NK-based tumor immunotherapy has been an important arm of current immunotherapy research. However, improved efficacy of NK-based immunotherapy requires a better understanding of NK cell biology.
T-bet is a central transcription factor for NK cells, governing multiple processes including the development, maturation and function of NK cells. The expression of T-bet is dynamically and finely regulated in various disease conditions, as well as in different development stages or functional status of NK cells, which should impact its role in regulating NK cell activity. In this review, we’ll discuss the expression regulation and functions of T-bet, with an emphasis on NK cells. Based on the knowledge of the expression regulation and function of T-bet in NK cells, we also discuss potential immunotherapy strategies that could exploit the anti-tumor capacity of NK cells in future.
An Overview of T-Bet in the Immune System
T-Bet in NK Cells
T-bet is a key transcription factor for natural killer cell maturation (12). T-bet expression correlates with NK cell maturation during the process from less mature CD11bposCD27pos stage to the more mature CD11bposCD27neg stage. Deficiency of T-bet leads to significantly reduced NK cell numbers, as well as the lack of TRAIL+DX5- NK cells. In addition, Eomes–deficient NK precursors could not develop into NK cells if T-bet is also deficient, as NK cells could not be detected in any organs in Tbx21−/−EomesFlox/Flox; Vav-Cre+ mice (13). Therefore, T-bet coordinates with Eomes for the development of NK cells, and T-bet is required for NK cell maturation (14–16). T-bet is also important for NK cell effector functions. Although T-bet-/- NK cells can also rapidly secrete IFN-γ compared with wild-type NK cells, the maintenance of IFN-γ production is impaired in the absence of T-bet. Besides, the cytolytic activity of T-bet−/− NK cells against target cells was significantly reduced (14). The above aspects will be discussed in detail in the later sections of this review.
T-Bet in T Cells
T cell differentiation is essential for the outcome of immune responses in diseases (17). T-bet plays an important role in the regulation of differentiation of T cell subsets, which is orchestrated by the activity of a series of transcription factors (18). T-bet promotes Th1 differentiation, but inhibits Th2, Th17 and Tfh cell lineage commitment (6, 19). T-bet regulates Treg cell homeostasis and promoted T-bet+ Treg cells to accumulate at sites of Th1-mediated inflammation by inducing expression of the chemokine receptor CXCR3 on Treg cells (20). CD8+T cells that have high T-bet levels tend to become terminally differentiated effector cells, whereas the cells that have low T-bet levels have a higher memory cell developmental potential (21).
T-Bet in Other Immune Cells
In addition to NK cells and T cells, T-bet also regulates other lymphocyte populations. T-bet acts as a selective inducer for the expression of Iγ2a transcription, and promotes IFN-γ-mediated IgG2a class-switching in B cells (22). IFN-γ/T-bet–dependent pathway regulates CXCR3 expression in B cells to drive the migration of memory B cells to inflammatory foci (23). On the other hand, T-bet is expressed in DCs at levels comparable with Th1 cells and is necessary for the production of IFN-γ and activation of antigen-specific Th1 cells (24). Moreover, T-bet suppresses intestine IL-17A –producing ILCs, which are potent promoters of ulcerative colitis, by decreasing the expression of IL-7 receptor in these cells (25). IL-2 and IL-15 are structurally related cytokines that share common receptor subunit-CD122 (IL-2 receptor β chain) (26). T-bet is required for optimal CD122 expression on thymic intraepithelial lymphocyte precursors (12), as well as on Vα14i NKT cells (14) for their development or maturation.
Regulation of T-Bet Expression
T-Bet Expression Is Induced by IFN-γR/STAT1 Pathway
IFN-γ plays a critical role in regulation of Th1 cell development (27). After 6 or 24h of anti-CD3 stimulation, IFN-γ -producing Th1 cells, but not Th2 cells, increased T-bet expression. After infection of a prototypical Th1-inducing pathogen, Toxoplasma gondii, splenic Tbx21 mRNA levels increased 4-fold in wild type mice, but not in Ifnγ−/−mice, indicating that IFN-γ is essential in inducing T-bet expression (28). Naive CD4+ T cells from lymph nodes of 5C.C7 T cell receptor transgenic/Rag2-deficient mice incubated with APCs increased expression of T-bet in T cells in the presence, but not in the absence, of TCR –specific peptide and IFN-γ, indicating that T-bet could be induced in response to TCR stimulation in an IFN-γ–dependent manner (28). Furthermore, IFN-γ stimulation failed to induce T-bet in Stat1-deficient mice (29). The above evidence suggests that T-bet is induced in T cells by TCR through the IFN-γR/STAT1 signaling pathway.
Moreover, three potential T-box binding sites were detected in Ifnγ gene, two of which were located in the proximal promoter region and one in the third intron (5), showing that T-bet is a transactivator of the Ifnγ gene and mediates positive feed-forward regulation of endogenous IFN-γ production.
T-Bet Expression Is Induced by IL-12R/STAT4 Pathway
Besides IFN-γ, IL-12 is also involved in the differentiation of naive T lymphocytes into Th1 cells (30, 31), and could also induce the expression of T-bet. Although IL-12 could be an inducer of IFN-γ, Ifngr−/− T cells increased T-bet expression after stimulation with IL-12 (32), indicating that IL-12 induces T-bet expression independent of IFN-γ. In support of this, chromatin immunoprecipitation showed that the conserved T-bet enhancer element 13 kilobases upstream of the transcriptional start site can interact with IL-12–activatedSTAT4 to induce T-bet expression (33). Purified splenic NK cells from wild-type, Ifnγ−/−, and Stat4−/− mice stimulated with IL-12/IL-18 for 12h showed that IL-12 induced the expression of T-bet through STAT4 independently of IFN-γ (14). Therefore, early after TCR stimulation, T-bet expression is mainly induced through the TCR/IFN-γ signaling pathway, when the expression of IL-12 receptor β2 subunit is repressed by TCR signaling, whereas in the later phase, this repression is removed upon termination of TCR stimulation, allowing T-bet induction through STAT4 downstream of IL-12R signaling pathway (Figure 1).
Figure 1 The regulation of T-bet expression in NK cells. IFN-γ binds to IFN-γR and regulates the expression of T-bet through JAK-STAT1 pathway. IL-12 induces T-bet expression independent of IFN-γ through JAK-STAT4 pathway. IL15 activates PI3K-AKT-mTORC1signaling axis to promote the expression of T-bet, whereas Foxo1 downstream of mTORC2 can inhibit the expression of T-bet in NK cells. IL-21 can activate the JAK-STAT3 pathway, and the activated STAT3 combines with MyD88 to activate the downstream NK-κB pathway to up-regulate the expression of T-bet.
T-Bet Expression Is Induced by TLR/MyD88 Pathway
MyD88 is a TIR-domain-containing adaptor protein in response to Toll-like receptors in TLR signaling pathway (34). MyD88 is located downstream of the TLR (except TLR3) and IL-1 receptor family, and transmits signals to activate NF-κB and MAP kinases and to induce inflammatory cytokines (35). 3 weeks after naïve CD4+ T cells from WT donors were transferred into congenic WT or MyD88 deficient recipient mice, the differentiation of T-bethigh memory-phenotype (MP) cells was significantly fewer in MyD88 deficient recipient mice than in WT mice, which indicates that extrinsic TLR-MyD88 signaling plays a key role in driving MP cells to differentiate into T-bethigh subpopulations (36). B cell TLR signaling has been reported to induce T-bet expression to produce IgG2A/cAb in response to viral infection (37, 38). Immunization with Qβ-VLP of irradiated chimeric mice of mixed bone marrow cells from WT (CD45.1+) and MyD88 KO (CD45.2+) showed that T-bet expression in MyD88 KO derived Qβ+ B cells from chimeric mice was much lower than that in WT-derived cells, which suggests that B cell-intrinsic MyD88 signaling was required for T-bet expression (39). On the other hand, IL-21 can induce STAT3 to bind to MyD88 activated sequence (GAS) and SIE (a well-characterized element binding activated STAT3), leading to up-regulation of T-bet expression in NK cells (40). This indicates that IL-21 may regulate T-bet expression in NK cells through the JAK-STAT3-MyD88 axis.
T-Bet Expression Is Promoted by mTOR Signaling Pathway
mTOR binds to Raptor and Rictor to form two complexes, mTORC1 and mTORC2, respectively (41). The activity of mTOR could be stimulated via IL-15 signaling in NK cells (42), which plays an important role in NK cell effector functions (43). The absence of either mTORC1 or mTORC2 led to decreased expression of T-bet by NK cells (44, 45). Tsc1 (a repressor of mTOR) negatively regulated IL-15-triggered mTORC1 activation in NK cells. TSC1 deficiency resulted in higher activity of mTORC1 in Tsc1−/− NK cells than in WT NK cells. Meanwhile, T-bet was expressed at a higher level in Tsc1−/− NK cells compared with WT NK cells (46). Six phosphorylation sites of T-bet were identified to be targets of mTORC1, among which at least three sites were required for recruitment of chromatin remodeling complexes to the Ifng gene promoter by T-bet for a normal level of IFN-γ production (47). These studies indicate that T-bet expression is promoted by mTOR signaling pathway (Figure 2).
Figure 2 The functions of T-bet in NK cells. T-bet promotes the transcription of genes including Prf1, Gzmb and Runx1 to mediate NK cell cytotoxicity. T-bet positively regulates the secretion of IFN-γ to regulate immune responses. Through inducing the expression of Zeb2, T-bet promoted the differentiation from immature NK cells to mature NK cells. T-bet induces Zeb2, and Zeb2 binds to the S1pr5 promoter which promotes mature NK cells egress from lymph nodes and bone marrow to peripheral organs.
Posttranslational Protein Modification of T-Bet
The applications of T-bet reporter mice have facilitated the determination of T-bet expression level (6), which, together with intracellular staining for flow cytometry, have enabled the detection of T-bet expression level even in small lymphocyte populations that are difficult for western blot or Q-PCR. However, the activity of T-bet is regulated by posttranslational protein modifications (48), which could have made it more complex to assess T-bet activity. For example, IL-2 –inducible tyrosine kinase (ITK) phosphorylates the tyrosine residue Y525 of T-bet in Th cells after stimulation with TCR and IL-12, which is important for interaction with GATA-3 and for suppression of Th2 cell differentiation (49). In addition to phosphorylation by ITK, tyrosine residues Y219, Y265 and Y304 of T-bet are also phosphorylated by c-Abl, which is essential for IFN-γ production and suppression of Th2 cytokine production, and for control of allergic lung inflammation (50). Moreover, serine residue S508 phosphorylation is important for T-bet to interact with and prevent NF-κB p65 from binding to the Il2 promoter and for T-bet mediated suppression of IL-2 production in T cells (51). While the phosphorylation of tyrosine or serine residues in T-bet regulates the activity of T-bet, ubiquitination of lysine residues in T-bet affects both the activity and half-life of T-bet. Among 16 lysine residues of T-bet, although ubiquitination of the lysine residue K313 leads to proteasomal degradation of T-bet, such modification is important for T-bet’s DNA binding activity and T-bet –mediated suppression of IL-2 and Th2 cytokines (52). Future studies are required to determine the impact of posttranslational protein modifications of T-bet on NK cell biology.
The Role of T-Bet in NK Cell Immunity
T-Bet Maintains the Stability of Tissue-Resident NK Cells
T-bet was proposed to maintain the stability of immature NK cells, since TRAIL+DX5- NK cells were dramatically reduced in Tbx21−/− mice. Deletion of T-bet by treating Tbx21 flox/flox NK cells with TAT-Cre ex vivo resulted in the reduction of this population after transferred into Il2rg−/−Rag2−/− mice, confirming that T-bet stabilizes this NK cell subset (13). However, lack of T-bet was later shown to significantly reduce TRAIL+CD49a+CD49b- tissue-resident NK cells (trNK cells), which, though showing an immature phenotype, represents a lineage distinct from circulating conventional CD49a-CD49b+TRAIL- NK cells (53, 54). Therefore, the developmental stability of trNK cells is dependent on T-bet.
T-Bet Is Required for NK Cell Maturation
scRNA-seq revealed that more than 65% of T-bet-deficient NK cells were classified as the least mature iNK cluster, and the expression of immature NK signature genes was highly upregulated in T-bet-deficient NK cells (55). This shows that in the absence of T-bet the overall NK cell population displayed a more immature phenotype, indicating that T-bet is required for NK cell maturation. Mechanistically, T-bet induces and cooperates with Zeb2 to promote the transcription program for NK cell maturation, and induces S1P5 for mature NK cell egress from the bone marrow.
T-Bet Induces and Cooperates With Zeb2 to Promote NK Cell Maturation
The transcription factor Zeb2 (zinc finger E-box–binding homeobox 2) was among the most highly induced transcription factor during NK cell maturation. The mRNA expression level of Zeb2 in more mature CD27-NK cells is significantly higher than that in less mature CD11b-and DP NK cells. The number of mature CD27-NK cells in the spleen and bone marrow of NK-Zeb2Tg/+ and NK-Zeb2Tg/Tg mice is higher than that in wild-type mice, while the number of immature CD11b- and DP NK cells in these mice is lower. Therefore, Zeb2 expression promotes the maturation of NK cells. From percentage and absolute numbers of NK cells in the spleen and their maturation status as assessed by CD11b/CD27 staining, the phenotypes of mature NK cells from Tbx21-/- and Zeb2-/-mice were similar. The NK cells from Tbx21-/-, Tbx21+/-, WT and Tbx21 transgenic mice showed graded expression levels of Zeb2 mRNA in NK cells correlating with graded doses of T-bet (56). These findings indicate that Zeb2 acted downstream of T-bet, and that T-bet is necessary to induce Zeb2 expression. Hence, T-bet promotes terminal NK cell maturation by cooperating with Zeb2 (Figure 2).
T-Bet–Dependent S1P5 Promotes Egress of Mature NK Cells
Sphingosine-1-phosphate receptor 5 (S1P5), encoded by the gene S1pr5, is required for mature NK cell egress from the bone marrow to the peripheral (Figure 2). Chimeric mice with S1P5 deficient and wild-type bone marrow cells demonstrated a significant accumulation of S1P5-deficient NK cells in the BM and the lymph nodes (LNs). The ratio of S1P5deficient NK cells to wild-type NK cells in the lymphocytes was lower in the peripheral than in the LN (57–59). The expression level of S1pr5mRNA in T-bet deficient NK cells was significantly lower than that in wild-type NK cells (57). The expression of S1pr5 is induced by the positive feedback loop of T-bet and Zeb2, in which T-bet induces Zeb2, and Zeb2 binds to the S1pr5 promoter to initiate transcription (56, 60).
T-Bet Is Required for NK Cell Effector Functions
T-Bet Is Required for Sustained IFN-γ Production by NK Cells
IFN-γ is a critical effector cytokine produced by NK cells, playing important role in anti-tumor and anti-viral immune responses (61). In the absence of T-bet, early IFN-γ production by NK cells is not affected. However, after 24 hours of stimulation, the level of IFN-γ produced by T-bet-/-NK cells was significantly lower than that of WT mice. These findings indicate that the early and rapid secretion of IFN-γ is independent of T-bet, but T-bet expression is required for the maintenance of IFN-γ production by NK cells (14).
T-Bet Is Required for NK Cell Cytolytic Activity
In addition to the production of IFN-γ, the major effector function of NK cells also includes rapid production of perforin and granzymes for cytolysis of virally-infected or malignant cells (62–64). ChIP analysis of IL-12/IL-18-activated murine LAK cells showed that T-bet could bind to the promoter of Gzmb, Prf1 and Runx1. Both in resting NK cells and in IL-12 & IL-18 –stimulated NK cells, deficiency of T-bet led to decrease mRNA levels of these three genes (14). Therefore, T-bet promotes the transcription of genes including Prf1, Gzmb and Runx1to mediate NK cell cytolytic activity (Figure 2).
The Role of T-Bet in Diseases
T-Bet in Acute Infections
T-bet plays an important role in immune response against acute infections. In the process of infection with the intracellular bacterial pathogen Listeria monocytogenes (LM), T-bet enhances its own expression and IFN-γ production through the STAT1 signaling pathway, while the absence of T-bet may impair sustained secretion of IFN-γ by NK cells and T cells (65–67). In acute infection with LCMV Armstrong, loss of T-bet expression in Tfh cells suppressed Tfh expansion, and reduced the levels of germinal center B cells and plasma cells, as well as lower LCMV-specific IgG and subtype IgG2c titers in serum, indicating that T-bet is essential for Tfh response and antibody IgG2 class switching in acute LCMV infection (68). In addition, T-bet-/-mice displayed a compromised resistance to Mycobacterium tuberculosis infection, mainly due to impaired IFN-γ production from the CD4+Th1 T cell subset to form an effective type 1 immune response (69, 70). During the infection of intracellular parasite Toxoplasma gondii, dendritic cells and macrophages produce IL-12 to promote the activation and expansion of NK cells and T cells populations expressing high levels of T-bet and IFN-γ (71–75).
T-Bet in Inflammatory and Autoimmune Diseases
T-bet is critical for the development of immunopathology in the experimental autoimmune encephalomyelitis (EAE) model of inflammatory demyelination (76, 77). Importantly, T-bet–dependent NKp46+ ILCs are required for the initiation of CD4+ Th17 –mediated neuroinflammation (78). In Crohn’s disease, a chronic inflammatory disease of the gastrointestinal tract, T-bet protein expressed higher in lamina propria CD4+ T cells from patients than from healthy controls. The high expression of T-bet accelerates the development of Th1-mediated colitis, whereas mice lacking T-bet are more likely to develop Th2-mediated colitis (79, 80). In heart failure(HF), TCR –activated PKC-θ induces T-bet, which ultimately leads to the stimulation of immune response and the occurrence of cardiac hypertrophy and fibrosis (81). However, T-bet could act as a double-edged sword in response to inflammatory and autoimmune diseases as well. In cardiovascular disease (CVD), on the one hand, T-bet stimulates and activates the functions of immune cells such as NK and DC to increase inflammation and cardiac injury. On the other hand, T-bet activates regulatory T cells and stimulates angiogenesis to inhibit inflammation and replaces damaged vessels with new vessels (82). Besides, T-bet in B cells can regulate immunoglobulin (IgG) class switching. Increased T-bet expression in B cells inhibits IgE production and alleviates IgE-mediated allergic reactions and asthma (22, 83).
T-Bet in Tumors and Chronic Infections
T-bet-deficient mice generated in a transgenic adenocarcinoma mouse prostate model (TRAMP) indicated that lack of T-bet has little effect on the development of primary tumors, but that T-bet is needed to suppress metastasis (84). In addition, T-bet-deficient mice were extremely sensitive to the metastasis and spread of B16F10 melanoma cells (85). On the other hand, T-bet was down-regulated in adoptively transferred NK cells upon exposure to tumors and proliferation, which was associated with down-regulation of activating receptors and IFN-γ (86). T-bet mRNA level expressed by the exhausted NK cells of HBV individuals is lower than that of the NK cells of healthy donors (87). T-bet expression in virus-specific CD8+ T cells is also reduced during chronic infections, which negatively correlated with the expression of exhaustion marker PD-1 (88). Therefore, T-bet is critical for the control of tumors and chronic infections, but its expression might be downregulated in effector cells in these contexts.
Perspectives
T-Bet in NK–Based Immunotherapy
In NK-based tumor immunotherapy, the following strategies are currently under investigations to promote the anti-tumor effects of NK cells: 1.Blockade of the cell surface or intracellular inhibitory checkpoint molecules of NK cells (89–92); 2. Arming with chimeric antigen receptor (CAR) to improve tumor recognition specificity of NK cells (93, 94); 3. Bispecific antibody to connect NK cell activating receptor to target cells (95). Based on these technologies, as well as the knowledge on T-bet regulation and functions in NK cells, we can design strategies to promote the anti-tumor efficacy of NK –based immunotherapy.
Previous studies have shown that adoptive NK cell immunotherapy failed to effectively control tumors, which was associated with down-regulation of T-bet. Accordingly, we can further dissect the factors (inhibitory receptor-ligand interactions/soluble factors) responsible for the down-regulation of T-bet in tumor-associated NK cells, and design strategies to recover T-bet expression for maintaining the anti-tumor functions in NK cells. In line with this, small molecules potentially enhancing T-bet expression have been reported (96). Alternatively, ectopic expression of specific transcription factors in immune cells for tumor immunotherapy has also been reported (97, 98), T-bet –overexpressing CAR-T cells exhibited a Th1 phenotype with more effective anti-tumor activity, leading to improved survival of tumor-bearing mice (99). These studies suggest that the ectopic expression of T-bet in NK cells could be tested for tumor immunotherapy in future. In addition, based on knowledge on the cytokine receptors and signaling pathways responsible for inducing T-bet, we can rationally design the signaling domain of CAR-NK to trigger the T-bet –inducing pathways to promote the expression of T-bet for enhancing NK cell effector functions. Alternatively, we can design multi-specific antibody to trigger T-bet –inducing cytokine receptors to promote the expression of T-bet.
Open Questions/Future Studies on T-Bet in NK Cell Biology
T-bet and Eomes are highly homologous transcription factors, which play redundant or non-redundant roles as key checkpoints in the regulation of NK maturation (13). The synergistic cooperation between the two can better exert the effector function of NK cells for the control of tumors and infections. The balance between T-bet and Eomes in NK cell maturation, differentiation and effector function still requires further in-depth studies for the spatiotemporal effects of these transcription factors, the transcription elements that regulate the transcription of T-bet and Eomes, and the molecular chaperones that help them fold and assemble at the protein level. On the other hand, the regulation of T-bet expression in NK cells is closely related to the pathogenesis of various diseases. Further studies on the expression of T-bet in NK cells in disease models will better demonstrate the role of T-bet in NK cell biology. T-bet downregulation was shown to be one of the hallmarks of NK cell exhaustion in tumors, whose details still lack further elaboration, and might benefit future design of NK-based immunotherapy. Moreover, the human TBX21 gene has 40 known polymorphisms, of which one has been shown to be related to the susceptibility to type 1 diabetes (100), and the other is related to the incidence of herpes simplex virus 2 (101). However, the effect of T-bet polymorphisms on NK–dependent immune responses in human diseases is largely unknown. Therefore, from the angle of T-bet, our knowledge on NK cell biology is still limited. Further research on T-bet is essential, not only to expand our understanding of NK cells, but also to assist the design of future strategies of immunotherapy.
Author Contributions
CH and JB conceived and wrote the manuscript. All authors contributed to the article and approved the submitted version.
Funding
This work was supported by National Key R&D Program of China 2020YFA0710802 (JB), Natural Science Foundation of China 82071768 (JB), and Natural Science Foundation of Guangdong Province 2019A1515011412 (JB).
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Papaioannou VE. The T-Box Gene Family: Emerging Roles in Development, Stem Cells and Cancer. Development (2014) 141:3819–33. doi: 10.1242/dev.104471
2. Muller CW, Herrmann BG. Crystallographic Structure of the T Domain-DNA Complex of the Brachyury Transcription Factor. Nature (1997) 389:884–8. doi: 10.1038/39929
3. Smith J. T-Box Genes: What They do and How They do it. Trends Genet (1999) 15:154–8. doi: 10.1016/S0168-9525(99)01693-5
4. Papaioannou VE. T-Box Genes in Development: From Hydra to Humans. Int Rev Cytol (2001) 207:1–70. doi: 10.1016/S0074-7696(01)07002-4
5. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A Novel Transcription Factor, T-Bet, Directs Th1 Lineage Commitment. Cell (2000) 100:655–69. doi: 10.1016/S0092-8674(00)80702-3
6. Zhu J, Jankovic D, Oler AJ, Wei G, Sharma S, Hu G, et al. The Transcription Factor T-Bet Is Induced by Multiple Pathways and Prevents an Endogenous Th2 Cell Program During Th1 Cell Responses. Immunity (2012) 37:660–73. doi: 10.1016/j.immuni.2012.09.007
7. Szabo SJ, Sullivan BM, Peng SL, Glimcher LH. Molecular Mechanisms Regulating Th1 Immune Responses. Annu Rev Immunol (2003) 21:713–58. doi: 10.1146/annurev.immunol.21.120601.140942
8. Lazarevic V, Glimcher LH, Lord GM. T-Bet: A Bridge Between Innate and Adaptive Immunity. Nat Rev Immunol (2013) 13:777–89. doi: 10.1038/nri3536
9. Crinier A, Dumas PY, Escaliere B, Piperoglou C, Gil L, Villacreces A, et al. Single-Cell Profiling Reveals the Trajectories of Natural Killer Cell Differentiation in Bone Marrow and a Stress Signature Induced by Acute Myeloid Leukemia. Cell Mol Immunol (2021) 18:1290–304. doi: 10.1038/s41423-020-00574-8
10. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of Natural Killer Cells. Nat Immunol (2008) 9:503–10. doi: 10.1038/ni1582
11. Bi J, Wang X. Molecular Regulation of NK Cell Maturation. Front Immunol (2020) 11:1945. doi: 10.3389/fimmu.2020.01945
12. Klose CS, Blatz K, d’Hargues Y, Hernandez PP, Kofoed-Nielsen M, Ripka JF, et al. The Transcription Factor T-Bet Is Induced by IL-15 and Thymic Agonist Selection and Controls CD8alphaalpha(+) Intraepithelial Lymphocyte Development. Immunity (2014) 41:230–43. doi: 10.1016/j.immuni.2014.06.018
13. Gordon SM, Chaix J, Rupp LJ, Wu J, Madera S, Sun JC, et al. The Transcription Factors T-Bet and Eomes Control Key Checkpoints of Natural Killer Cell Maturation. Immunity (2012) 36:55–67. doi: 10.1016/j.immuni.2011.11.016
14. Townsend MJ, Weinmann AS, Matsuda JL, Salomon R, Farnham PJ, Biron CA, et al. T-Bet Regulates the Terminal Maturation and Homeostasis of NK and Valpha14i NKT Cells. Immunity (2004) 20:477–94. doi: 10.1016/S1074-7613(04)00076-7
15. Daussy C, Faure F, Mayol K, Viel S, Gasteiger G, Charrier E, et al. T-Bet and Eomes Instruct the Development of Two Distinct Natural Killer Cell Lineages in the Liver and in the Bone Marrow. J Exp Med (2014) 211:563–77. doi: 10.1084/jem.20131560
16. Knox JJ, Cosma GL, Betts MR, McLane LM. Characterization of T-Bet and Eomes in Peripheral Human Immune Cells. Front Immunol (2014) 5:217. doi: 10.3389/fimmu.2014.00217
17. Yoshitomi H, Ueno H. Shared and Distinct Roles of T Peripheral Helper and T Follicular Helper Cells in Human Diseases. Cell Mol Immunol (2021) 18:523–7. doi: 10.1038/s41423-020-00529-z
18. Sheikh AA, Groom JR. Transcription Tipping Points for T Follicular Helper Cell and T-Helper 1 Cell Fate Commitment. Cell Mol Immunol (2021) 18:528–38. doi: 10.1038/s41423-020-00554-y
19. Kallies A, Good-Jacobson KL. Transcription Factor T-Bet Orchestrates Lineage Development and Function in the Immune System. Trends Immunol (2017) 38:287–97. doi: 10.1016/j.it.2017.02.003
20. Koch MA, Tucker-Heard G, Perdue NR, Killebrew JR, Urdahl KB, Campbell DJ. The Transcription Factor T-Bet Controls Regulatory T Cell Homeostasis and Function During Type 1 Inflammation. Nat Immunol (2009) 10:595–602. doi: 10.1038/ni.1731
21. Chang JT, Ciocca ML, Kinjyo I, Palanivel VR, McClurkin CE, Dejong CS, et al. Asymmetric Proteasome Segregation as a Mechanism for Unequal Partitioning of the Transcription Factor T-Bet During T Lymphocyte Division. Immunity (2011) 34:492–504. doi: 10.1016/j.immuni.2011.03.017
22. Peng SL, Szabo SJ, Glimcher LH. T-Bet Regulates IgG Class Switching and Pathogenic Autoantibody Production. Proc Natl Acad Sci USA (2002) 99:5545–50. doi: 10.1073/pnas.082114899
23. Serre K, Cunningham AF, Coughlan RE, Lino AC, Rot A, Hub E, et al. CD8 T Cells Induce T-Bet-Dependent Migration Toward CXCR3 Ligands by Differentiated B Cells Produced During Responses to Alum-Protein Vaccines. Blood (2012) 120:4552–9. doi: 10.1182/blood-2012-03-417733
24. Lugo-Villarino G, Maldonado-Lopez R, Possemato R, Penaranda C, Glimcher LH. T-Bet is Required for Optimal Production of IFN-Gamma and Antigen-Specific T Cell Activation by Dendritic Cells. Proc Natl Acad Sci USA (2003) 100:7749–54. doi: 10.1073/pnas.1332767100
25. Powell N, Walker AW, Stolarczyk E, Canavan JB, Gokmen MR, Marks E, et al. The Transcription Factor T-Bet Regulates Intestinal Inflammation Mediated by Interleukin-7 Receptor+ Innate Lymphoid Cells. Immunity (2012) 37:674–84. doi: 10.1016/j.immuni.2012.09.008
26. Votavova P, Tomala J, Kovar M. Increasing the Biological Activity of IL-2 and IL-15 Through Complexing With Anti-IL-2 Mabs and IL-15ralpha-Fc Chimera. Immunol Lett (2014) 159:1–10. doi: 10.1016/j.imlet.2014.01.017
27. Bradley LM, Dalton DK, Croft M. A Direct Role for IFN-Gamma in Regulation of Th1 Cell Development. J Immunol (1996) 157:1350–8.
28. Lighvani AA, Frucht DM, Jankovic D, Yamane H, Aliberti J, Hissong BD, et al. T-Bet Is Rapidly Induced by Interferon-Gamma in Lymphoid and Myeloid Cells. Proc Natl Acad Sci USA (2001) 98:15137–42. doi: 10.1073/pnas.261570598
29. Afkarian M, Sedy JR, Yang J, Jacobson NG, Cereb N, Yang SY, et al. T-Bet Is a STAT1-Induced Regulator of IL-12R Expression in Naive CD4+ T Cells. Nat Immunol (2002) 3:549–57. doi: 10.1038/ni794
30. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O’Garra A, Murphy KM. Development of TH1 CD4+ T Cells Through IL-12 Produced by Listeria-Induced Macrophages. Science (1993) 260:547–9. doi: 10.1126/science.8097338
31. Manetti R, Parronchi P, Giudizi MG, Piccinni MP, Maggi E, Trinchieri G, et al. Natural Killer Cell Stimulatory Factor (Interleukin 12 [IL-12]) Induces T Helper Type 1 (Th1)-Specific Immune Responses and Inhibits the Development of IL-4-Producing Th Cells. J Exp Med (1993) 177:1199–204. doi: 10.1084/jem.177.4.1199
32. Schulz EG, Mariani L, Radbruch A, Hofer T. Sequential Polarization and Imprinting of Type 1 T Helper Lymphocytes by Interferon-Gamma and Interleukin-12. Immunity (2009) 30:673–83. doi: 10.1016/j.immuni.2009.03.013
33. Yang Y, Ochando JC, Bromberg JS, Ding Y. Identification of a Distant T-Bet Enhancer Responsive to IL-12/Stat4 and IFNgamma/Stat1 Signals. Blood (2007) 110:2494–500. doi: 10.1182/blood-2006-11-058271
34. Kawai T, Akira S. The Role of Pattern-Recognition Receptors in Innate Immunity: Update on Toll-Like Receptors. Nat Immunol (2010) 11:373–84. doi: 10.1038/ni.1863
35. Kawai T, Akira S. Toll-Like Receptors and Their Crosstalk With Other Innate Receptors in Infection and Immunity. Immunity (2011) 34:637–50. doi: 10.1016/j.immuni.2011.05.006
36. Kawabe T, Yi J, Kawajiri A, Hilligan K, Fang D, Ishii N, et al. Requirements for the Differentiation of Innate T-Bet(High) Memory-Phenotype CD4(+) T Lymphocytes Under Steady State. Nat Commun (2020) 11:3366. doi: 10.1038/s41467-020-17136-1
37. Gerth AJ, Lin L, Peng SL. T-Bet Regulates T-Independent IgG2a Class Switching. Int Immunol (2003) 15:937–44. doi: 10.1093/intimm/dxg093
38. Rubtsova K, Rubtsov AV, van Dyk LF, Kappler JW, Marrack P. T-Box Transcription Factor T-Bet, a Key Player in a Unique Type of B-Cell Activation Essential for Effective Viral Clearance. Proc Natl Acad Sci USA (2013) 110:E3216–24. doi: 10.1073/pnas.1312348110
39. Tian M, Hua Z, Hong S, Zhang Z, Liu C, Lin L, et al. B Cell-Intrinsic MyD88 Signaling Promotes Initial Cell Proliferation and Differentiation To Enhance the Germinal Center Response to a Virus-Like Particle. J Immunol (2018) 200:937–48. doi: 10.4049/jimmunol.1701067
40. Strengell M, Sareneva T, Foster D, Julkunen I, Matikainen S. IL-21 Up-Regulates the Expression of Genes Associated With Innate Immunity and Th1 Response. J Immunol (2002) 169:3600–5. doi: 10.4049/jimmunol.169.7.3600
41. Laplante M, Sabatini DM. mTOR Signaling at a Glance. J Cell Sci (2009) 122:3589–94. doi: 10.1242/jcs.051011
42. Marcais A, Cherfils-Vicini J, Viant C, Degouve S, Viel S, Fenis A, et al. The Metabolic Checkpoint Kinase mTOR is Essential for IL-15 Signaling During the Development and Activation of NK Cells. Nat Immunol (2014) 15:749–57. doi: 10.1038/ni.2936
43. Nandagopal N, Ali AK, Komal AK, Lee SH. The Critical Role of IL-15-PI3K-mTOR Pathway in Natural Killer Cell Effector Functions. Front Immunol (2014) 5:187. doi: 10.3389/fimmu.2014.00187
44. Li D, Wang Y, Yang M, Dong Z. Mtorc1 and Mtorc2 Coordinate Early NK Cell Development by Differentially Inducing E4BP4 and T-Bet. Cell Death Differ (2021) 28(6):1900–09. doi: 10.1038/s41418-020-00715-6
45. Wang F, Meng M, Mo B, Yang Y, Ji Y, Huang P, et al. Crosstalks Between Mtorc1 and Mtorc2 Variagate Cytokine Signaling to Control NK Maturation and Effector Function. Nat Commun (2018) 9:4874. doi: 10.1038/s41467-018-07277-9
46. Yang M, Chen S, Du J, He J, Wang Y, Li Z, et al. NK Cell Development Requires Tsc1-Dependent Negative Regulation of IL-15-Triggered Mtorc1 Activation. Nat Commun (2016) 7:12730. doi: 10.1038/ncomms12730
47. Chornoguz O, Hagan RS, Haile A, Arwood ML, Gamper CJ, Banerjee A, et al. Mtorc1 Promotes T-Bet Phosphorylation To Regulate Th1 Differentiation. J Immunol (2017) 198:3939–48. doi: 10.4049/jimmunol.1601078
48. Oh S, Hwang ES. The Role of Protein Modifications of T-Bet in Cytokine Production and Differentiation of T Helper Cells. J Immunol Res (2014) 2014:589672. doi: 10.1155/2014/589672
49. Hwang ES, Szabo SJ, Schwartzberg PL, Glimcher LH. T Helper Cell Fate Specified by Kinase-Mediated Interaction of T-Bet With GATA-3. Science (2005) 307:430–3. doi: 10.1126/science.1103336
50. Chen A, Lee SM, Gao B, Shannon S, Zhu Z, Fang D. C-Abl-Mediated Tyrosine Phosphorylation of the T-Bet DNA-Binding Domain Regulates CD4+ T-Cell Differentiation and Allergic Lung Inflammation. Mol Cell Biol (2011) 31:3445–56. doi: 10.1128/MCB.05383-11
51. Hwang ES, Hong JH, Glimcher LH. IL-2 Production in Developing Th1 Cells is Regulated by Heterodimerization of RelA and T-Bet and Requires T-Bet Serine Residue 508. J Exp Med (2005) 202:1289–300. doi: 10.1084/jem.20051044
52. Jang EJ, Park HR, Hong JH, Hwang ES. Lysine 313 of T-Box is Crucial for Modulation of Protein Stability, DNA Binding, and Threonine Phosphorylation of T-Bet. J Immunol (2013) 190:5764–70. doi: 10.4049/jimmunol.1203403
53. Sojka DK, Yang L, Yokoyama WM. Uterine Natural Killer Cells. Front Immunol (2019) 10:960. doi: 10.3389/fimmu.2019.00960
54. Sojka DK, Plougastel-Douglas B, Yang L, Pak-Wittel MA, Artyomov MN, Ivanova Y, et al. Tissue-Resident Natural Killer (NK) Cells Are Cell Lineages Distinct From Thymic and Conventional Splenic NK Cells. Elife (2014) 3:e01659. doi: 10.7554/eLife.01659
55. Yang C, Siebert JR, Burns R, Zheng Y, Mei A, Bonacci B, et al. Single-Cell Transcriptome Reveals the Novel Role of T-Bet in Suppressing the Immature NK Gene Signature. Elife (2020) 9:e51339. doi: 10.7554/eLife.51339
56. van Helden MJ, Goossens S, Daussy C, Mathieu AL, Faure F, Marcais A, et al. Terminal NK Cell Maturation is Controlled by Concerted Actions of T-Bet and Zeb2 and is Essential for Melanoma Rejection. J Exp Med (2015) 212:2015–25. doi: 10.1084/jem.20150809
57. Jenne CN, Enders A, Rivera R, Watson SR, Bankovich AJ, Pereira JP, et al. T-Bet-Dependent S1P5 Expression in NK Cells Promotes Egress From Lymph Nodes and Bone Marrow. J Exp Med (2009) 206:2469–81. doi: 10.1084/jem.20090525
58. Mayol K, Biajoux V, Marvel J, Balabanian K, Walzer T. Sequential Desensitization of CXCR4 and S1P5 Controls Natural Killer Cell Trafficking. Blood (2011) 118:4863–71. doi: 10.1182/blood-2011-06-362574
59. Walzer T, Chiossone L, Chaix J, Calver A, Carozzo C, Garrigue-Antar L, et al. Natural Killer Cell Trafficking In Vivo Requires a Dedicated Sphingosine 1-Phosphate Receptor. Nat Immunol (2007) 8:1337–44. doi: 10.1038/ni1523
60. Zhang J, Marotel M, Fauteux-Daniel S, Mathieu AL, Viel S, Marcais A, et al. T-Bet and Eomes Govern Differentiation and Function of Mouse and Human NK Cells and ILC1. Eur J Immunol (2018) 48:738–50. doi: 10.1002/eji.201747299
61. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-Gamma: An Overview of Signals, Mechanisms and Functions. J Leukoc Biol (2004) 75:163–89. doi: 10.1189/jlb.0603252
62. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural Killer Cells in Antiviral Defense: Function and Regulation by Innate Cytokines. Annu Rev Immunol (1999) 17:189–220. doi: 10.1146/annurev.immunol.17.1.189
63. Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ, et al. Cytotoxicity Mediated by T Cells and Natural Killer Cells Is Greatly Impaired in Perforin-Deficient Mice. Nature (1994) 369:31–7. doi: 10.1038/369031a0
64. Pardo J, Balkow S, Anel A, Simon MM. Granzymes are Essential for Natural Killer Cell-Mediated and Perf-Facilitated Tumor Control. Eur J Immunol (2002) 32:2881–7. doi: 10.1002/1521-4141(2002010)32:10<2881::AID-IMMU2881>3.0.CO;2-K
65. Busch DH, Kerksiek K, Pamer EG. Processing of Listeria Monocytogenes Antigens and the In Vivo T-Cell Response to Bacterial Infection. Immunol Rev (1999) 172:163–9. doi: 10.1111/j.1600-065X.1999.tb01364.x
66. Frucht DM, Fukao T, Bogdan C, Schindler H, O’Shea JJ, Koyasu S. IFN-Gamma Production by Antigen-Presenting Cells: Mechanisms Emerge. Trends Immunol (2001) 22:556–60. doi: 10.1016/S1471-4906(01)02005-1
67. Way SS, Wilson CB. Cutting Edge: Immunity and IFN-Gamma Production During Listeria Monocytogenes Infection in the Absence of T-Bet. J Immunol (2004) 173:5918–22. doi: 10.4049/jimmunol.173.10.5918
68. Wang P, Wang Y, Xie L, Xiao M, Wu J, Xu L, et al. The Transcription Factor T-Bet Is Required for Optimal Type I Follicular Helper T Cell Maintenance During Acute Viral Infection. Front Immunol (2019) 10:606. doi: 10.3389/fimmu.2019.00606
69. Sullivan BM, Jobe O, Lazarevic V, Vasquez K, Bronson R, Glimcher LH, et al. Increased Susceptibility of Mice Lacking T-Bet to Infection With Mycobacterium Tuberculosis Correlates With Increased IL-10 and Decreased IFN-Gamma Production. J Immunol (2005) 175:4593–602. doi: 10.4049/jimmunol.175.7.4593
70. Mitsos LM, Cardon LR, Fortin A, Ryan L, LaCourse R, North RJ, et al. Genetic Control of Susceptibility to Infection With Mycobacterium Tuberculosis in Mice. Genes Immun (2000) 1:467–77. doi: 10.1038/sj.gene.6363712
71. Gazzinelli RT, Hakim FT, Hieny S, Shearer GM, Sher A. Synergistic Role of CD4+ and CD8+ T Lymphocytes in IFN-Gamma Production and Protective Immunity Induced by an Attenuated Toxoplasma Gondii Vaccine. J Immunol (1991) 146:286–92.
72. Khan IA, Matsuura T, Kasper LH. Interleukin-12 Enhances Murine Survival Against Acute Toxoplasmosis. Infect Immun (1994) 62:1639–42. doi: 10.1128/iai.62.5.1639-1642.1994
73. Sher A, Collazzo C, Scanga C, Jankovic D, Yap G, Aliberti J. Induction and Regulation of IL-12-Dependent Host Resistance to Toxoplasma Gondii. Immunol Res (2003) 27:521–8. doi: 10.1385/IR:27:2-3:521
74. Lieberman LA, Banica M, Reiner SL, Hunter CA. STAT1 Plays a Critical Role in the Regulation of Antimicrobial Effector Mechanisms, But Not in the Development of Th1-Type Responses During Toxoplasmosis. J Immunol (2004) 172:457–63. doi: 10.4049/jimmunol.172.1.457
75. Harms PG, Hall AO, Christian DA, Wagage S, Fang Q, Muallem G, et al. Diverse Roles for T-Bet in the Effector Responses Required for Resistance to Infection. J Immunol (2015) 194:1131–40. doi: 10.4049/jimmunol.1401617
76. Bettelli E, Sullivan B, Szabo SJ, Sobel RA, Glimcher LH, Kuchroo VK. Loss of T-Bet, But Not STAT1, Prevents the Development of Experimental Autoimmune Encephalomyelitis. J Exp Med (2004) 200:79–87. doi: 10.1084/jem.20031819
77. Lovett-Racke AE, Rocchini AE, Choy J, Northrop SC, Hussain RZ, Ratts RB, et al. Silencing T-Bet Defines a Critical Role in the Differentiation of Autoreactive T Lymphocytes. Immunity (2004) 21:719–31. doi: 10.1016/j.immuni.2004.09.010
78. Kwong B, Rua R, Gao Y, Flickinger J Jr., Wang Y, Kruhlak MJ, et al. T-Bet-Dependent NKp46(+) Innate Lymphoid Cells Regulate the Onset of TH17-Induced Neuroinflammation. Nat Immunol (2017) 18:1117–27. doi: 10.1038/ni.3816
79. Neurath MF, Weigmann B, Finotto S, Glickman J, Nieuwenhuis E, Iijima H, et al. The Transcription Factor T-Bet Regulates Mucosal T Cell Activation in Experimental Colitis and Crohn’s Disease. J Exp Med (2002) 195:1129–43. doi: 10.1084/jem.20011956
80. Matsuoka K, Inoue N, Sato T, Okamoto S, Hisamatsu T, Kishi Y, et al. T-Bet Upregulation and Subsequent Interleukin 12 Stimulation Are Essential for Induction of Th1 Mediated Immunopathology in Crohn’s Disease. Gut (2004) 53:1303–8. doi: 10.1136/gut.2003.024190
81. Solomou EE, Keyvanfar K, Young NS. T-Bet, a Th1 Transcription Factor, is Up-Regulated in T Cells From Patients With Aplastic Anemia. Blood (2006) 107:3983–91. doi: 10.1182/blood-2005-10-4201
82. Haybar H, Rezaeeyan H, Shahjahani M, Shirzad R, Saki N. T-Bet Transcription Factor in Cardiovascular Disease: Attenuation or Inflammation Factor? J Cell Physiol (2019) 234:7915–22. doi: 10.1002/jcp.27935
83. Liu N, Ohnishi N, Ni L, Akira S, Bacon KB. CpG Directly Induces T-Bet Expression and Inhibits IgG1 and IgE Switching in B Cells. Nat Immunol (2003) 4:687–93. doi: 10.1038/ni941
84. Peng SL, Townsend MJ, Hecht JL, White IA, Glimcher LH. T-Bet Regulates Metastasis Rate in a Murine Model of Primary Prostate Cancer. Cancer Res (2004) 64:452–5. doi: 10.1158/0008-5472.CAN-03-3401
85. Werneck MB, Lugo-Villarino G, Hwang ES, Cantor H, Glimcher LH. T-Bet Plays a Key Role in NK-Mediated Control of Melanoma Metastatic Disease. J Immunol (2008) 180:8004–10. doi: 10.4049/jimmunol.180.12.8004
86. Gill S, Vasey AE, De Souza A, Baker J, Smith AT, Kohrt HE, et al. Rapid Development of Exhaustion and Down-Regulation of Eomesodermin Limit the Antitumor Activity of Adoptively Transferred Murine Natural Killer Cells. Blood (2012) 119:5758–68. doi: 10.1182/blood-2012-03-415364
87. Li H, Zhai N, Wang Z, Song H, Yang Y, Cui A, et al. Regulatory NK Cells Mediated Between Immunosuppressive Monocytes and Dysfunctional T Cells in Chronic HBV Infection. Gut (2018) 67:2035–44. doi: 10.1136/gutjnl-2017-314098
88. Kao C, Oestreich KJ, Paley MA, Crawford A, Angelosanto JM, Ali MA, et al. Transcription Factor T-Bet Represses Expression of the Inhibitory Receptor PD-1 and Sustains Virus-Specific CD8+ T Cell Responses During Chronic Infection. Nat Immunol (2011) 12:663–71. doi: 10.1038/ni.2046
89. Andre P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, et al. Anti-NKG2A mAb Is a Checkpoint Inhibitor That Promotes Anti-Tumor Immunity by Unleashing Both T and NK Cells. Cell (2018) 175:1731–43.e13. doi: 10.1016/j.cell.2018.10.014
90. Zhang Q, Bi J, Zheng X, Chen Y, Wang H, Wu W, et al. Blockade of the Checkpoint Receptor TIGIT Prevents NK Cell Exhaustion and Elicits Potent Anti-Tumor Immunity. Nat Immunol (2018) 19:723–32. doi: 10.1038/s41590-018-0132-0
91. Bi J, Tian Z. NK Cell Dysfunction and Checkpoint Immunotherapy. Front Immunol (2019) 10:1999. doi: 10.3389/fimmu.2019.01999
92. Ben-Shmuel A, Biber G, Sabag B, Barda-Saad M. Modulation of the Intracellular Inhibitory Checkpoint SHP-1 Enhances the Antitumor Activity of Engineered NK Cells. Cell Mol Immunol (2021) 18:1314–6. doi: 10.1038/s41423-020-0443-6
93. Hu Y, Tian ZG, Zhang C. Chimeric Antigen Receptor (CAR)-Transduced Natural Killer Cells in Tumor Immunotherapy. Acta Pharmacol Sin (2018) 39:167–76. doi: 10.1038/aps.2017.125
94. Wang W, Jiang J, Wu C. CAR-NK for Tumor Immunotherapy: Clinical Transformation and Future Prospects. Cancer Lett (2020) 472:175–80. doi: 10.1016/j.canlet.2019.11.033
95. Li H, Er SP, Song E. Challenges and Strategies for Next-Generation Bispecific Antibody-Based Antitumor Therapeutics. Cell Mol Immunol (2020) 17:451–61. doi: 10.1038/s41423-020-0417-8
96. Thome R, Boehm A, Ishikawa LLW, Casella G, Munhoz J, Ciric B, et al. Chloroquine Reduces Th17 Cell Differentiation by Stimulating T-Bet Expression in T Cells. Cell Mol Immunol (2021) 18:779–80. doi: 10.1038/s41423-020-0432-9
97. Shan Q, Hu S, Chen X, Danahy DB, Badovinac VP, Zang C, et al. Ectopic Tcf1 Expression Instills a Stem-Like Program in Exhausted CD8(+) T Cells to Enhance Viral and Tumor Immunity. Cell Mol Immunol (2021) 18:1262–77. doi: 10.1038/s41423-020-0436-5
98. Dumauthioz N, Tschumi B, Wenes M, Marti B, Wang H, Franco F, et al. Enforced PGC-1alpha Expression Promotes CD8 T Cell Fitness, Memory Formation and Antitumor Immunity. Cell Mol Immunol (2021) 18:1761–71. doi: 10.1038/s41423-020-0365-3
99. Gacerez AT, Sentman CL. T-Bet Promotes Potent Antitumor Activity of CD4(+) CAR T Cells. Cancer Gene Ther (2018) 25:117–28. doi: 10.1038/s41417-018-0012-7
100. Sasaki Y, Ihara K, Matsuura N, Kohno H, Nagafuchi S, Kuromaru R, et al. Identification of a Novel Type 1 Diabetes Susceptibility Gene, T-Bet. Hum Genet (2004) 115:177–84. doi: 10.1007/s00439-004-1146-2
Keywords: Tbx21, Eomes, Th1, tumor immunology, immunotherapy
Citation: Huang C and Bi J (2021) Expression Regulation and Function of T-Bet in NK Cells. Front. Immunol. 12:761920. doi: 10.3389/fimmu.2021.761920
Received: 20 August 2021; Accepted: 20 September 2021;
Published: 05 October 2021.
Edited by:
Cai Zhang, Shandong University, ChinaReviewed by:
Hui Peng, University of Science and Technology of China, ChinaPeixiang Lan, Huazhong University of Science and Technology, China
Copyright © 2021 Huang and Bi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jiacheng Bi, jc.bi@siat.ac.cn